NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









KangaBio

KangaBio

Private
ShanghaiHealthcare & Life Scienceshttps://www.kangabio.com/about

Last Round

VC Round

Nov 1, 2025

Total Funding Raised

$41M

Company Overview

KangaBio is a biopharmaceutical company that specializes in the discovery and development of novel cancer immunotherapies, including prodrugs of immune agonists and multispecific antibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

prodrug technologytumor immunotherapybispecific antibodyoncology biotechtumor microenvironmentimmune modulatorcontract development and manufacturing organizationCDMOclinical-stage biotechdrug discoveryprotein engineeringnext-gen oncologyprecision oncologybiologicstargeted cancer therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KangaBio Comparables

Compare KangaBio with similar companies based on industry and business-model similarity.

KangaBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CytomX Therapeutics
83%
Bonum Therapeutics
83%
AskGene Pharma
82%

KangaBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundNov 1, 2025
Early FundingJun 23, 2023
AngelAug 1, 2021

KangaBio Investors

Notable investors and investment history

KangaBio investors
InvestorRounds
Tianjin TEDA Science and Technology Investment Co., Ltd.Early Funding
Daoyuan CapitalEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2021

    $11M raised in an angel round.

KangaBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KangaBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KangaBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingNov 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.